AU Patent

AU2002349299A1 — Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes

Assigned to Novo Nordisk AS · Expires 2003-06-17 · 23y expired

What this patent protects

Patent listed against Tradjenta.

Drugs covered by this patent

Patent Metadata

Patent number
AU2002349299A1
Jurisdiction
AU
Classification
—
Expires
2003-06-17
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.